BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 30775858)

  • 1. Lung cancer family history and exposure to occupational/domestic coal combustion contribute to variations in clinicopathologic features and gene fusion patterns in non-small cell lung cancer.
    Chen Y; Li G; Lei Y; Yang K; Niu H; Zhao J; He R; Ning H; Huang Q; Zhou Q; Huang Y
    Thorac Cancer; 2019 Apr; 10(4):695-707. PubMed ID: 30775858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Detection of ALK, ROS1 and RET fusion genes in non-small cell lung cancer patients and its clinicopathologic correlation].
    Zhong S; Zhang H; Bai D; Gao D; Zheng J; Ding Y
    Zhonghua Bing Li Xue Za Zhi; 2015 Sep; 44(9):639-43. PubMed ID: 26705279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
    Ke L; Xu M; Jiang X; Sun X
    Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients.
    Song Z; Yu X; Zhang Y
    Cancer Biol Ther; 2017 Nov; 18(11):883-887. PubMed ID: 27635639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinic-pathologic features and gene fusion pattern of ALK and ROS1 in non-small cell lung cancer show association with household coal combustion.
    Chen Y; Huang Y; Ning H; Chen X; Tan X; Ding X
    Transl Cancer Res; 2019 Sep; 8(5):2164-2174. PubMed ID: 35116966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion.
    Furugaki K; Mochizuki M; Kohno M; Shu S; Harada N; Yoshimura Y
    BMC Cancer; 2019 Apr; 19(1):301. PubMed ID: 30943926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
    Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
    Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of
    Reguart N; Teixidó C; Giménez-Capitán A; Paré L; Galván P; Viteri S; Rodríguez S; Peg V; Aldeguer E; Viñolas N; Remon J; Karachaliou N; Conde E; Lopez-Rios F; Nadal E; Merkelbach-Bruse S; Büttner R; Rosell R; Molina-Vila MA; Prat A
    Clin Chem; 2017 Mar; 63(3):751-760. PubMed ID: 28073897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.
    Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y
    Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement.
    Antonescu CR; Suurmeijer AJ; Zhang L; Sung YS; Jungbluth AA; Travis WD; Al-Ahmadie H; Fletcher CD; Alaggio R
    Am J Surg Pathol; 2015 Jul; 39(7):957-67. PubMed ID: 25723109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical features of 54 cases of lung adenocarcinomas with c-ROS oncogene 1 fusion].
    Cao H; Zheng J; Zhao J; Guo XJ; Zhou JY; Ding W; Zhou JY
    Zhonghua Jie He He Hu Xi Za Zhi; 2020 Feb; 43(2):120-125. PubMed ID: 32062881
    [No Abstract]   [Full Text] [Related]  

  • 12. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
    Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
    J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression and copy number gains of the RET gene in 631 early and mid stage non-small cell lung cancer cases.
    Tan L; Hu Y; Tao Y; Wang B; Xiao J; Tang Z; Lu T; Tang H
    Thorac Cancer; 2018 Apr; 9(4):445-451. PubMed ID: 29473341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
    Kim HR; Lim SM; Kim HJ; Hwang SK; Park JK; Shin E; Bae MK; Ou SH; Wang J; Jewell SS; Kang DR; Soo RA; Haack H; Kim JH; Shim HS; Cho BC
    Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.
    Zito Marino F; Rossi G; Cozzolino I; Montella M; Micheli M; Bogina G; Munari E; Brunelli M; Franco R
    J Clin Pathol; 2020 Feb; 73(2):96-101. PubMed ID: 31562206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decoding Tumor Phenotypes for ALK, ROS1, and RET Fusions in Lung Adenocarcinoma Using a Radiomics Approach.
    Yoon HJ; Sohn I; Cho JH; Lee HY; Kim JH; Choi YL; Kim H; Lee G; Lee KS; Kim J
    Medicine (Baltimore); 2015 Oct; 94(41):e1753. PubMed ID: 26469915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare.
    Zhao W; Choi YL; Song JY; Zhu Y; Xu Q; Zhang F; Jiang L; Cheng J; Zheng G; Mao M
    Lung Cancer; 2016 Apr; 94():22-7. PubMed ID: 26973202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].
    Chen LF; Chen XY; Yu XB
    Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):221-5. PubMed ID: 27033383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ROS1 fusions in Chinese patients with non-small-cell lung cancer.
    Cai W; Li X; Su C; Fan L; Zheng L; Fei K; Zhou C; Manegold C; Schmid-Bindert G
    Ann Oncol; 2013 Jul; 24(7):1822-1827. PubMed ID: 23514723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity.
    Kimura H; Nakajima T; Takeuchi K; Soda M; Mano H; Iizasa T; Matsui Y; Yoshino M; Shingyoji M; Itakura M; Itami M; Ikebe D; Yokoi S; Kageyama H; Ohira M; Nakagawara A
    Lung Cancer; 2012 Jan; 75(1):66-72. PubMed ID: 21757253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.